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Introduction. Sarcoidosis is a multisystemic granulomatous disorder characterized by multiple noncaseating granulomas involving
intrathoracic lymph nodes and lung parenchyma. Recently, the use of anti-tumor necrosis factor alpha (anti-TNF𝛼) agents has
been introduced for therapy of chronic and refractory sarcoidosis with controversial results. Infliximab (Remicade) is a chimeric
monoclonal antibody (mAb) that recognizes and binds TNF𝛼, neutralizing its biological effects. In the present study, 99mTc labelled
infliximab was used to study the expression of TNF𝛼 in sarcoid lesions and to evaluate its role as a predictive marker in response to
therapy with Remicade.Material and Methods. A total of 10 patients with newly diagnosed sarcoidosis were enrolled together with
10 control patients affected by rheumatoid arthritis. All patients were studied by planar imaging of the chest with 99mTc-infliximab
at 6 h and 24 h and total body [18F]-FDG PET/CT. Regions of interest were drawn over the lungs and the right arm and target-
to-background ratios were analysed for 99mTc-infliximab. SUVmean and SUVmax were calculated over lungs for FDG. Results and
Discussion. Image analysis showed low correlation between T/B ratios and BAL results in patients despite positivity at [18F]-FDG
PET. Conclusion. In conclusion, patients with newly diagnosed pulmonary sarcoidosis, with FDG-PET and BAL positivity, showed
a negative 99mTc-infliximab scintigraphy.
1. Introduction
Sarcoidosis is a multisystemic granulomatous disorder char-
acterized by multiple noncaseating granulomas involving
intrathoracic lymph nodes and lung parenchyma. Inflamma-
tory lesions can occur also in other organs like eyes and skin
and, although less frequently, also in liver, spleen, extratho-
racic lymph nodes, salivary glands, heart, nervous system,
bones, and muscles. Even if its aetiology is still unknown,
the role of cell-mediated immunity in the formation and in
the maintenance of typical granulomas has been clarified [1,
2]. For this reason immunosuppressive therapy remains the
gold standard for treatment and in particular corticosteroid
are used as a first line therapy [3]. However, serious side
effects of steroid therapy and the loss of long-term efficacy
of this treatment have led researchers to use new drugs.
Recently, the use of anti-tumor necrosis factor alpha (anti-
TNF𝛼) agents has been introduced for therapy of chronic and
refractory sarcoidosis [4–6]. TNF𝛼 is an important cytokine
released by alveolar activated macrophages, implicated in
the development of granulomas. Infliximab (Remicade) is a
chimeric monoclonal antibody (mAb) that recognizes and
binds TNF𝛼, neutralizing its biological effects [7]. However,
the effectiveness of such therapy is still uncertain and under
investigation [8]. It is indeed not well known if TNF𝛼 is
sufficiently present in sarcoid lesions to play a relevant
biological role despite the fact that its presence in BAL has
been shown to correlate with the severity of alveolitis [9].
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Nevertheless, which patient and which lesion have high levels
of TNF𝛼 and may respond to anti-TNF𝛼 therapy is difficult
to ascertain. In this view, the assessment of TNF𝛼 in sarcoid
lesions by a noninvasive technique could be important to
strengthen the hypothesis behind the use of anti-TNF𝛼 drugs
and to select patients that could respond to therapy. Currently
there are no specific diagnostic tools to directly evaluate the
presence of anti-TNF𝛼 in sarcoid lesions but several methods
have been reported for measuring disease activity. Chest X-
ray and pulmonary function tests (spirometry), the measure-
ment of serum angiotensin-converting-enzyme (ACE) levels
and 67Ga-citrate scintigraphy, and bronchoalveolar lavage
(BAL) with evaluation of CD4+ and CD8+ lymphocytes
have all been and still are used as surrogate markers of
diseases activity [10, 11]. In particular, [18F]-Fluoro-2-deoxy-
D-glucose PET/CT ([18F]-FDG PET/CT) has been shown to
be of high clinical value for evaluation of disease activity and
extent and for therapy follow-up [12–15].
In the present study, we have used 99mTechnetium
(99mTc) labelled infliximab in patients with newly diagnosed
sarcoidosis for noninvasive in vivo scintigraphic evaluation of
the presence of TNF𝛼 in pulmonary and lymph nodal sarcoid
lesions. Patients were also studied by [18F]-FDG PET/CT and
BAL with lymphocyte phenotyping for complete evaluation
of disease activity.
2. Patients and Methods
2.1. Patients andDiagnosis. Study design included 20 patients
with newly diagnosed sarcoidosis at stages II-III to be
prospectively recruited for [18F]-FDG-PET/CT and 99mTc-
infliximab scintigraphy and 10 control subjects (patients
without sarcoidosis but affected by rheumatoid arthritis (RA)
to evaluate disease activity in joints). After enrolling all
controls (7 females and 3 males, mean age 54 ± 10 years)
and 10 sarcoidosis patients (8 females and 2 males, mean age
55 ± 8 years) we performed an interim analysis and decided
to stop recruitment, based on results. Sarcoidosis patients
were symptomatic and presented respiratory symptoms of
the disease, without involvement of specific organs but lungs,
thoracic and extrathoracic lymph nodes. They were also
subjected to a standard assessment that included history and
physical examination, with particular attention to respiratory
disorders, blood test with peripheral blood counts and
lymphocytes count ratio, and X-ray examination of the chest,
including X-ray and high-resolution CT, bronchoscopy with
bronchoalveolar lavage and bronchial biopsy, and analysis
of BAL with lymphocytes immune-phenotyping (2 patients
refused to perform the BAL).Thediagnosis of sarcoidosis was
performed using histological demonstration of the presence
of the typical noncaseating granulomas; other diseases such
as Wegener’s granulomatosis, tuberculosis, aspergillosis, and
neoplastic diseases were excluded for each patient. None of
enrolled patients had previously been treated with corticos-
teroid therapy or immunosuppressive drugs. The study was
approved by the local medical ethical committee and each
patient expressed written informed consensus.
2.2. [18F]-FDG PET/CT. Within 2 months from clinical
diagnosis of sarcoidosis, a [18F]-FDGPET/CTwas performed
after fasting for at least 6 h before the intravenous injection
of [18F]-FDG and with a serum glucose level lower than
160mg/dL. Diazepam (5mg) was administered to reduce
muscle activity and activation of the brown fat. The activity
of [18F]-FDG to be administered was calculated for each
patient according to the following formula [(weight in
Kg/10 × 37MBq) + 1]. The PET scan was performed with
hybrid PET/CT Gemini (Philips, NL). Imaging acquisition
started 60 minutes after the radiopharmaceutical injection
from the upper thigh to the head, with a preliminary low-
dose unenhanced CT scan (16 slice, 100mAs) followed by
PET imaging (2.5min per bed position, 3D mode, matrix).
Images were reconstructedwithCTdata by common iterative
algorithm (OSEM, ordered subset expectationmaximization,
2 iterations, 28 subsets) to obtain attenuation corrected
images and anatomical mapping on functional images. [18F]-
FDG PET/CT images were visually analysed and disease
activity was assessed separately in the mediastinum, hilum,
lung parenchyma, extrapulmonary lymph nodes, even with
obvious evaluation of liver, spleen, bone marrow, bones,
and joints, in order to highlight a possible involvement of
these organs. Each site was scored either positive or nega-
tive (positive = [18F]-FDG uptake higher than background;
negative = [18F]-FDG uptake lower or equal to background).
The semiquantitative analysis was based on the analysis of
standardized uptake value (SUV) evaluated as SUVmax and
SUVmean, obtained by drawing regions of interest (ROIs) on
transaxial sections of lung parenchyma at the level of the
3rd, 5th, and 7th thoracic vertebral body. The SUV values
obtained were then compared with those obtained in the
control population.
2.3. 99m𝑇𝑐-Infliximab Scintigraphy. The mAb infliximab was
radiolabelled as previously described [16]. Briefly, 200𝜇L of
99mTcO
4
− (666MBq) was added to 200𝜇L of reduced mAb
(200mg/mL) followed by 7 𝜇L of methylene diphosphonate
(MDP). After 10 minutes of incubation at room temperature,
quality controls were performed by instant thin layer chro-
matography (ITLC). Silica gel strips and 0.9% NaCl solution
were used, respectively, as stationary and mobile phase for
labelling efficiency determination. Albumin precoated silica
gel strips and H
2
O : EtOH :NH
3
(5 : 3 : 1) solution were used
for colloids evaluation.
Within 1 week from the PET/CT scan, all patients per-
formed a scintigraphic study with radiolabelled anti-TNF𝛼
after intravenous injection of 370MBq of 99mTc-infliximab.
Whole body images and planar static images of chest were
acquired at 6 h and 24 h after injection with a large field
of view, two head, gamma camera (Sky Light, Philips, NL)
equipped with low-energy high-resolution collimators and
20% energy windows centred at 140KeV.Whole body images
(matrix 512 × 1024) were acquired at a speed of 10 cm/min at
6 h and 5 cm/min at 24 h taking into account the decay of the
radionuclide. Anterior and posterior thorax images (matrix
256 × 256) were acquired for 300 seconds at 6 h and 600
seconds at 24 h.
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Figure 1: 99mTc-Infliximab scintigraphy of a sarcoidosis patient (patient 3/F) acquired at 6 h (anterior and posterior views (a)) and at 24 h
(anterior and posterior views (b)) showing a moderate and diffuse uptake in the lung parenchyma. [18F]-FDG PET/CT images of the same
patient showing a focal/hyleal uptake (coronal and transaxial sections (c)).
The results of scintigraphic studies were qualitatively
analysed to identify any labelled mAb uptake and were
visually compared with the pathological findings on PET
images. A semiquantitative analysis was performed drawing
ROIs over each lung parenchyma (ROIlung) including hilum,
but excluding heart and spine, and a ROI over the upper right
arm (ROIarm) as background, excluding joints. The counts
were normalized by area and the target-to-background (T/B)
ratio (ROIlung/ROIarm) was calculated at 6 h and 24 h for
each lung in anterior and in posterior views. The average
value of anterior and posterior values was considered for each
patient. Results were compared with control subjects that
underwent 99mTc-infliximab for RA and therefore considered
“pulmonary negative.”
2.4. Statistical Analysis. For each patient the average values
of SUVmax and SUVmean, obtained in lung parenchyma, were
calculated in both sarcoidosis patients and controls, obtaining
for each group the mean value ± SD. Similarly, the mean
values ± SD of T/B ratios in sarcoidosis patients and control
group were calculated at each time point (6 h and 24 h).
In sarcoidosis population correlations were made between
mean SUV values and mean T/B ratio, mean SUV values
and lymphocytes immune-phenotyping on BAL, and mean
T/B ratio and lymphocytes immune-phenotyping on BAL, in
order to assess the diagnostic accuracy of each methodology
to evaluate disease activity. Student’s 𝑡-test was applied to
assess the significance of relationship between the T/B ratio
of sarcoidosis group and T/B ratio of control subjects.
3. Results
3.1. [18F]-FDG PET/TC. The qualitative analysis performed
on PET/CT studies in lungs showed complete agreementwith
the staging previously made by pulmonologists according
to radiological and biochemical findings (Figure 1). Further-
more, in 3/10 patients PET showed other extrapulmonary
sites of disease, with involvement of axillary and abdominal-
pelvic lymph nodes, not previously known, demonstrating its
high sensitivity.Themean values ± SD of SUVmax obtained in
patients with sarcoidosis were 4.43 ± 3.20 whereas in control
subjects mean values ± SD of SUVmax were 1.18 ± 0.20 (𝑃 <
0.001).These data are an expression of inflammation involve-
ment of lung parenchyma in patients with sarcoidosis. The
values of SUVmax and SUVmean correlated perfectly; therefore
for subsequent analysis only SUVmax will be reported even
if also SUVmean has always been considered. Despite the
higher values of SUVmax in patients with sarcoidosis with
respect to controls, it was not possible to find a cut-off
value that could allow the correlation of the extent of uptake
in the lung parenchyma with the degree of alveolitis. It
was not also possible to obtain a significant correlation
between lymphocyte immune-phenotyping results of BAL
(with particular reference to CD4+/CD8+ ratio) and the
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Table 1: Summary of SUV obtained by [18F]-FDG PET/CT and T/B values (average of right and left lung calculated in anterior and posterior
images) in patients with sarcoidosis.
Number/Sex Stage SUVmax SUVmean 𝑇/𝐵 6 h 𝑇/𝐵 24 h
1/F I 1.91 0.54 4.16 2.84
2/F II 3.47 0.99 4.34 2.75
3/F II 4.38 2.19 3.52 3.49
4/F II 2.64 0.79 4.82 3.97
5/M I-II 3.05 1.02 3.61 3.14
6/F II 5.28 1.25 4.77 3.24
7/M I 2.23 0.73 4.14 2.72
8/F II 12.87 4.55 4.73 3.41
9/F II 3.01 0.88 3.43 2.49
10/F II 5.48 0.90 4.73 3.42
Mean ± SD 4.43 ± 3.2 1.38 ± 1.2 4.22 ± 0.55 3.15 ± 0.45
SUVmax values of patients with sarcoidosis. No correlation
was also observed between SUVmax or SUVmean values and
the CD4+/CD8+ ratio in blood.
3.2. 99m𝑇𝑐-Infliximab Scintigraphy. Thequalitative analysis of
scintigraphy with 99mTc-infliximab showed no pathological
focal accumulation of the labeled antibody (Table 1). Both
images at 6 h, characterized by high vascular activity, and
images at 24 h did not show the same pathological uptakes
highlighted in the preliminary PET study (Figures 1 and 2).
The pulmonary distribution of the two radiopharmaceuticals
was different, being predominantly diffused in the case of
99mTc-infliximab and rather focal with ileal involvement in
the PET scans.
Comparing T/B ratios on 99mTc-infliximab scintigraphy
at 6 h and 24 h, with SUVmax values of pulmonary uptake
of FDG, no significant correlation was observed between
these parameters. In only three patients a detectable diffuse
bilateral lung uptake of anti-TNF𝛼 at 6 h and 24 h on scinti-
graphic images was present, which could indicate increased
levels of TNF𝛼 in lung parenchyma of these patients. When
we compared the mean values of lung uptake of labelled
anti-TNF𝛼mAb in sarcoidosis patients and control subjects,
we found significant differences at 6 h (4.28 ± 0.57 versus
3.2 ± 0.74; patients versus controls; 𝑃 = 0.002) but not at
24 h (3.15 ± 0.45 versus 2.7 ± 0.65; patients versus controls;
𝑃 = 0.057). A moderate correlation was found between
CD4+/CD8+ ratio peripheral blood lymphocytes and the
value of T/B ratio at 6 h (Figure 3) but no correlation was
found between average value of T/B ratio at 6 h or 24 h
and, respectively, CD4+/CD8+ ratio and cellularity of BAL
(Figure 4).
4. Discussion
In the last decade, systemic autoimmune disease therapy
has been revolutionized by the availability of biological
drugs or monoclonal antibodies, directed against a specific
target implicated in the pathogenesis of disease. In patients
with active sarcoidosis, the release of TNF𝛼 by activated
alveolar macrophages has been widely documented in a
lot of previous studies [17–21]. Infliximab (Remicade) is a
chimeric monoclonal antibody of the type IgG1𝜅, with a
variable region derived from murine antihuman TNF𝛼 and
a constant sequence of human-derived IgG1. It was one of
the first biological drugs to be used for the treatment of
patients with sarcoidosis refractory to conventional therapy
[5, 6, 22–24]. In particular, the multicenter phase II study of
Baughman et al. [25] showed that in patients with sarcoidosis,
symptomatic, refractory to corticosteroid therapy, treated
with infliximab, there was a significant improvement of the
forced vital capacity (FVC) without significant side effects
related to the use of the drug. However, Panselinas et al.
[26] showed, in a retrospective study, that in the majority
of patients treated with infliximab, there was a recurrence of
the disease about 3 months after discontinuation of the drug.
Since biological therapies, such as infliximab, are extremely
expensive, it would be desirable to be able to accurately
select patients who really might benefit from this type of
therapies. To date, however, there are no diagnostic markers
for therapy decisionmaking. In order to answer this question,
we undertook a study to assess whether scintigraphy with
99mTc-infliximab, showing directly the presence of TNF𝛼 in
the lesions, may represent amarker for predicting the efficacy
of biological therapy with anti-TNF𝛼 and then select the
patients suitable for this type of treatment [27, 28]. Infliximab
was labelled with high labelling efficiency, high specific
activity, and stability. Preliminary studies in vitro in animals
and humans have shown its usefulness in the evaluation of
patients with Crohn’s disease and rheumatoid arthritis [29–
31]. [18F]-FDG PET has proven to be a very sensitive method
in the evaluation of disease activity.Many studies have shown
its higher sensitivity compared to 67Gallium-citrate scintig-
raphy in the evaluation of disease and follow-up of therapy
[14, 32–38]. However, [18F]-FDG PET lacks specificity and
cannot be used for the selection of patients to be treated with
anti-TNF𝛼. Itsmain role remains the diagnostic confirmation
of disease, evaluation of the extension of the sites of disease,
and the follow-up. It is therefore right to compare the role
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Figure 2: 99mTc-Infliximab scintigraphy of a sarcoidosis patient (patient 4/F) acquired at 6 h (anterior and posterior views (a)) and at 24 h
(anterior and posterior views (b)) showing a moderate and diffuse uptake in the lung parenchima. [18F]-FDG PET/CT images of the same
patient showing a focal/hyleal uptake (coronal and transaxial sections (c)).
0.00
1.00
2.00
3.00
4.00
5.00
6.00
0 0.5 1 1.5 2 2.5
CD4+/CD8+ ratio in blood
T
/
B
ra
tio
6
h
Figure 3: Correlation between lung uptake of 99mTc-infliximab
at 6 h (T/B ratio) and CD4+/CD8+ ratio in peripheral blood
lymphocytes. Correlation coefficient is 𝑟 = 0.2357 and 𝑃 = 0.05.
of scintigraphy with 99mTc-infliximab in the evaluation of
disease with the findings obtained with [18F]-FDG PET, but
mainly for the selection of patients suitable for treatmentwith
unlabelled anti-TNF𝛼 mAb. From our data, although on a
limited series, it appears that with a qualitative examination,
PET confirmed the staging performed by pulmonologists and
allowed us to identify locations of extrathoracic disease, like
axillaries and abdominopelvic lymph nodes. Inflammatory
events in the lung parenchyma of sarcoidosis patients have
been confirmed by higher SUVmax and SUVmean with respect
to normal subjects. The lack of correlation between the
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Figure 4: Correlation between lung uptake of 99mTc-infliximab at
6 h (T/B ratio) and CD4+/CD8+ ratio in lymphocytes from BAL.
Correlation coefficient is 𝑟 = 0.6487 and 𝑃 = n.s.
CD4+/CD8+ lymphocytes ratio in BAL and the values of both
SUVmax and SUVmean in the lung could be explained by the
fact that the [18F]-FDG is taken up by various cell types
involved in the inflammatory sarcoid granuloma, confirming
its poor specificity. Alternatively BAL is performed in a
single lung segment whereas SUV was calculated over the
whole lungs. Scintigraphy with labelled anti-TNF𝛼mAb was
qualitatively positive in 4 out of 10 patients, showing at 6 h
and 24 h a widespread uptake of the radiopharmaceutical in
both lungs.The values of T/B ratio calculated, on both the 6 h
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and 24 h images, did not correlate with the values of SUVmax
and SUVmean calculated on ROIlung of PET.
There are many possible explanations for this different
pattern of 18F-FDG and 99mTc-infliximab in sarcoidosis
patients. One of them is that the two radiopharmaceuticals
show different aspects of the same phenomenon: the intense
[18F]-FDG uptake by the cell populations responsible of
alveolitis (macrophages, lymphocytes, etc.) and the presence
of TNF𝛼 revealed by radiolabelled 99mTc-infliximab. Alterna-
tively, theremay be individual variability in the production of
TNF𝛼 due to genetic reasons that depend on the stage of the
disease.The lack of a clear focal uptake in some patients could
also be caused by the long half-life of the anti-TNF𝛼 mAb
that resulted in high background activity from the blood.This
phenomenon is critical in highly perfused organs such as the
lungs. In this case, the use of isotopes with longer half-life
(89Zr or 111In) could help allowing to acquire images at later
time points (e.g., 48 h or 72 h) thus improvingT/B ratio due to
clearance of radiopharmaceutical from the blood. Moreover,
it should be kept in mind that, contrarily to what happens
in lesions where the targets of a radiopharmaceutical are
membrane bound receptors, TNF𝛼 is also a soluble molecule
and a possible washout or low concentration in the lesions
could prevent the visualization of distinctive foci. Indeed,
on the basis of the review of literature, the most responsive
patients to therapy with infliximab appear to be those with
extrapulmonary disease, with involvement of skin, nervous
system, bone, and ocular disease; it would be interesting to
study these patients with 99mTc-infliximab scintigraphy in
order to effectively assess the presence of TNF𝛼 in other
extrapulmonary tissues affected by sarcoidosis.
Our choice was to investigate patients with newly diag-
nosed sarcoidosis that did not undergo prior therapies, based
on the need to study “naive” patients in which no previous
immunosuppressive therapy was administered. Despite what
we expected the T/B ratio calculated at 6 h and 24 h did not
correlate with the amount of lymphocytes in BAL, indicating
that not all immune-mediated phenomena are characterized
by high production of TNF𝛼.
5. Conclusions
Labelled anti-TNF𝛼 mAb scintigraphy could be a good
tool for the selection of patients to be treated with anti-
TNF𝛼 drugs; however, in our study most of the examined
patients showed a negative 99mTc-infliximab scintigraphy,
underlining a low presence of TNF𝛼 even if [18F]-FDG
PET/CT was highly positive.
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